The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; Genentech; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Merck; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Roche/Genentech (Inst)
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Daniel Castellano
No Relationships to Disclose
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); Roche/Genentech (Inst)
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Novartis
 
Daniel Peter Petrylak
Honoraria - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Celgene; Dendreon; Johnson & Johnson; Millennium; Oncogenex; Progenics; Sanofi
Travel, Accommodations, Expenses - Bayer; Bellicum Pharmaceuticals; Celgene; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Oncogenex; Pfizer; Progenics; Sanofi
 
Jon Armstrong
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Riccardo Belli
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Salvatore Ferro
Employment - AstraZeneca
Stock and Other Ownership Interests - Amgen
 
Yong Ben
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer